Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) will present its 2026 company milestones at the Biotech Showcase in San Francisco on January 13, 2026.
CEO Helen Tayton-Martin will deliver the company update on Tuesday, January 13, 2026 at 2:00 PM PST / 11:00 PM CET on Track: Yosemite C (Ballroom Level). The Biotech Showcase runs January 12-14, 2026 and coincides with the J.P. Morgan Healthcare Conference; Evaxion plans stakeholder meetings and investor engagement throughout the week.
Contact: Mads Kronborg, Vice President Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, EVAX gained 6.73%, reflecting a notable positive market reaction. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Biotech peers show mixed moves: GOVX appeared on the momentum scanner with a 4.6% move up, while other close peers like PULM, IBIO, LSTA and SYBX had varied directions, suggesting stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Collaboration update | Negative | -18.3% | MSD declined EVX‑B2 option, Evaxion retained global rights and seeks partner. |
| Nov 20 | Preclinical data | Positive | +9.4% | New CMV EVX‑V1 preclinical data showing immune responses and viral inhibition. |
| Nov 12 | Financial calendar | Neutral | +0.7% | Published 2026 schedule for business updates and quarterly financial results. |
| Nov 07 | Clinical data update | Positive | +1.9% | Phase 2 EVX‑01 immune and biomarker data presented at SITC 2025. |
| Nov 06 | Earnings and pipeline | Positive | +10.6% | Q3 2025 results with strong EVX‑01 data, EVX‑B3 deal and extended runway. |
Recent news with clearly positive clinical or financial content tended to see aligned positive price reactions, while partnership setbacks saw aligned downside.
Over the last few months, Evaxion has combined clinical progress with corporate updates. Q3 2025 results highlighted a 75% ORR for EVX‑01, a lucrative EVX‑B3 MSD deal and cash runway into the second half of 2027, with shares reacting +10.6%. Positive preclinical data for CMV program EVX‑V1 and new immune data for EVX‑01 also saw gains. By contrast, retaining EVX‑B2 rights after MSD declined its option coincided with an -18.26% move. Today’s conference milestone preview fits into that ongoing communication cadence.
Market Pulse Summary
The stock moved +6.7% in the session following this news. A strong positive reaction aligns with prior instances where clear visibility into strategy or data coincided with gains, such as the Q3 2025 update at +10.6% and CMV EVX‑V1 data at +9.43%. However, past downside after collaboration shifts, like the -18.26% move on the EVX‑B2 update, shows sentiment can reverse if follow‑up milestones, partnerships or financing steps disappoint.
Key Terms
ai-immunology medical
techbio technical
AI-generated analysis. Not financial advice.
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion’s 2026 company milestones and provide a company update on January 13, 2026.
The Biotech Showcase conference coincides with the J.P. Morgan Healthcare Conference and Evaxion will engage with stakeholders in San Francisco, including potential business partners, throughout the week.
Presentation details:
Date: Tuesday, January 13, 2026
Time: 2:00pm PST/11:00pm CET
Track: Yosemite C (Ballroom Level)
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion (EVAX) present its 2026 milestones at Biotech Showcase?
Where is Evaxion's EVAX presentation at the Biotech Showcase being held?
Who will present Evaxion's company update at the January 13, 2026 session?
What are the Biotech Showcase event dates when EVAX will be meeting stakeholders?
How can investors contact Evaxion investor relations ahead of the EVAX presentation?
Will Evaxion (EVAX) hold meetings with potential partners during the conference week?
